Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of Clinical Pharmacology|August 9, 2014
Assessment of the effect of ofatumumab on cardiac repolarizationRoxanne C Jewell, Kevin Laubscher, Eric Lewis, et al.
International Journal of Hematology|January 6, 2026
Belantamab mafodotin, pomalidomide, and dexamethasone in Japanese patients with RRMM in the phase 3 DREAMM-8 trialKazutaka Sunami, Hiroshi Handa, Michiko Ichii, et al.
Leukemia & Lymphoma|February 28, 2015
An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemiaWilliam Nigel Patton, Robert Lindeman, Andrew C Butler, et al.
Nano Letters|December 9, 2017
Fluidic Microactuation of Flexible Electrodes for Neural RecordingFlavia Vitale, Daniel G Vercosa, Alexander V Rodriguez, et al.
American Heart Journal|July 12, 2011
Troponin measurements during drug development--considerations for monitoring and management of potential cardiotoxicity: an educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and Drug AdministrationL Kristin Newby, Ignacio Rodriguez, John Finkle, et al.
Cancer|July 27, 2021
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 studySagar Lonial, Hans C Lee, Ashraf Badros, et al.
Cancer|August 25, 2023
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trialAjay K Nooka, Adam D Cohen, Hans C Lee, et al.
Blood Advances|August 5, 2025
Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 TrialsMaria-Victoria Mateos, Suzanne Trudel, Hang Quach, et al.
The Lancet. Oncology|December 21, 2019
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 studySagar Lonial, Hans C Lee, Ashraf Badros, et al.
The New England Journal of Medicine|June 3, 2024
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple MyelomaVania Hungria, Pawel Robak, Marek Hus, et al.
Pageof 2